2019
DOI: 10.1136/bmjsrh-2018-chc
|View full text |Cite|
|
Sign up to set email alerts
|

FSRH Guideline (January 2019, amended October 2023) Combined Hormonal Contraception

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 356 publications
(208 reference statements)
0
3
0
Order By: Relevance
“…Long-acting reversible contraception (LARC) requires administration by a healthcare professional [17,22,23] – with the exception of the Sayana-Press (depot medroxyprogesterone acetate) subcutaneous injection [24]. Thus, due to the restrictions on face- to-face appointments, LARC administration severely decreased throughout the COVID-19 pandemic (Figure 3).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Long-acting reversible contraception (LARC) requires administration by a healthcare professional [17,22,23] – with the exception of the Sayana-Press (depot medroxyprogesterone acetate) subcutaneous injection [24]. Thus, due to the restrictions on face- to-face appointments, LARC administration severely decreased throughout the COVID-19 pandemic (Figure 3).…”
Section: Resultsmentioning
confidence: 99%
“…COVID-19 restrictions prevented the regular BMI and blood pressure monitoring required for safe COCP prescribing [17]. This likely led to the decrease seen in COCP prescribing and the growth in dispensing of POPs instead, which do not require the same patient monitoring [1719].…”
Section: Discussionmentioning
confidence: 99%
“…1 While changes are few, there are some important new recommendations relating to pill use patterns, reminders relating to safety and effectiveness, and new resources for clinicians.…”
mentioning
confidence: 99%